WuXi Diagnostics

WuXi Diagnostics (WXDX) is an integrated diagnostics company based in Shanghai, China, with additional facilities in Suzhou and an R&D center in Rochester, Minnesota.

Founded in 2018, WXDX is recognized for implementing integrated diagnostics at scale, combining advanced testing technologies, clinical data, and algorithms to enhance precision diagnosis and treatment. The company offers a wide range of diagnostic services, including specialized testing in oncology and complex conditions, companion diagnostic development, and clinical decision support. WXDX's core product is the Enabling Solution Package (ESP), which provides a comprehensive approach to disease management, integrating testing panels and medical insights. The company has developed nearly 100 biomarker testing methods and maintains a robust immunohistochemistry platform, supporting pharmaceutical companies in developing targeted therapies. WuXi Diagnostics collaborates with nearly 100 pharmaceutical and biotechnology companies globally, including a partnership with Cell Signaling Technology to co-develop companion diagnostic assays. The company’s infrastructure and expertise facilitate the efficient development and commercialization of diagnostic solutions, ultimately aiming to improve patient outcomes.